EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gene Therapy in Hemophilia: Clinical Advances, Immunological Challenges, and Emerging Therapeutic Perspectives

Agata Serrafi iD, Andrzej Wasilewski iD, Amelia Wawrzkiewicz, Anna Kałuża iD, Eliza Wasilewska iD

International Journal of Molecular Sciences · 28.04.2026 · 27 (9) · 3922

DOI: 10.3390/ijms27093922 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 28.04.2026. Verfasst von Agata Serrafi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Immunochemistry, Division of Chemistry and Immunochemistry, Wroclaw Medical University, M. Skłodowskiej-Curie 48/50, 5…. Hauptthemen laut MEDLINE: Genetic Therapy, Hemophilia A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapy is reshaping the therapeutic paradigm in hemophilia by enabling sustained endogenous clotting factor production after a single administration. This approach moves disease management beyond lifelong replacement therapy. While clinical trials have demonstrated marked reductions in bleeding rates and treatment burden, real-world implementation has revealed emerging complexities. These include interindividual variability in transgene expression reflected by a progressive reduction in circulating FVIII or FIX activity over time, uncertainty regarding the long-term durability of expression, immune-mediated constraints, and episodes of transaminase elevation. This review addresses a critical transition point in the field: the shift from proof-of-concept efficacy toward integration of gene therapy into long-term hemophilia care. We examine determinants of therapeutic stability, host–vector immune interactions, and mechanisms underlying loss or fluctuation of expression, with emphasis on monitoring strategies and post-therapy management pathways. Immunogenic processes affecting vector transduction, hepatocellular responses, and transgene persistence are discussed alongside current approaches to immune modulation. This review uniquely focuses on post-gene therapy clinical integration rather than vector design or trial outcomes. Beyond direct factor correction, evolving therapeutic concepts targeting coagulation rebalancing and immune regulation are considered within a systems-based framework. Psychosocial adaptation and patient-reported outcomes are also explored, underscoring that therapeutic success extends beyond hemostatic control. In aggregate, these perspectives position gene therapy not as a singular curative event but as a component of an evolving, biologically integrated management strategy. Long-term follow-up translational research (LTFU) and coordinated global efforts will be essential to optimize durability, safety, and equitable access.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyHemophilia AHumansAnimalsGenetic VectorsGene Therapy AgentsFactor IXFactor VIII

Stichwörter der Autor:innen

Adeno-associated virus (AAV) gene therapyHemgenixRoctavianhemophiliaimmunogenicitypost-gene therapy careviral vectors

Substanzen

Factor IXFactor VIII

Autor:innen und Institutionen

  • Department of Biochemistry and Immunochemistry, Division of Chemistry and Immunochemistry, Wroclaw Medical University, M. Skłodowskiej-Curie 48/50, 50-369 Wroclaw, Poland.
  • Student Scientific Association of Medical Chemistry and Immunochemistry, Wroclaw Medical University, M. Skłodowskiej-Curie 48/50, 50-369 Wroclaw, Poland.
  • Department of Allergology, Medical University of Gdansk, 80-214 Gdansk, Poland.
  • Center of Rare Disease, Centre University Hospital, 80-952 Gdansk, Poland.

ORCID-Profile: Agata Serrafi, Andrzej Wasilewski, Anna Kałuża, Eliza Wasilewska

Zitieren

APA

Serrafi, A., Wasilewski, A., Wawrzkiewicz, A., Kałuża, A., & Wasilewska, E. (2026). Gene Therapy in Hemophilia: Clinical Advances, Immunological Challenges, and Emerging Therapeutic Perspectives. International Journal of Molecular Sciences, 27(9), 3922. https://doi.org/10.3390/ijms27093922

Vancouver

Serrafi A, Wasilewski A, Wawrzkiewicz A, Kałuża A, Wasilewska E. Gene Therapy in Hemophilia: Clinical Advances, Immunological Challenges, and Emerging Therapeutic Perspectives. International Journal of Molecular Sciences. 2026;27(9):3922. doi:10.3390/ijms27093922

BibTeX
@article{Serrafi2026,
  author = {Serrafi, Agata and Wasilewski, Andrzej and Wawrzkiewicz, Amelia and Kałuża, Anna and Wasilewska, Eliza},
  title = {Gene Therapy in Hemophilia: Clinical Advances, Immunological Challenges, and Emerging Therapeutic Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {3922},
  doi = {10.3390/ijms27093922}
}
Kostenlos starten →